ADC Therapeutics SA shares fell nearly 53% in morning trading after a late-stage trial for its blood cancer drug reported higher patient deaths. The study tested Zynlonta alongside a Roche Holding AG-BR antibody in patients with relapsed or refractory diffuse large B-cell lymphoma. These results threaten the full United States regulatory approval required to maintain the drug's 2021 accelerated status.
ADC Therapeutics Shares Slump After Trial Patient Deaths
ADC Therapeutics shares fell nearly 53 percent after a late-stage study of its blood cancer drug Zynlonta showed 27 deaths in the treatment arm. While the drug met its primary goal for progression-free survival, the higher mortality rate among older patients has overshadowed the clinical results.
Xurve View
洞察:
Xurve View
### Mortality Rates Overshadow Efficacy Results ADC reported 27 deaths, or 13.2%, in the treatment arm compared to 9 deaths, or 4.6%, in the control group. Most deaths occurred in patients aged 75 or older, ADC said late evening the previous day. Control-arm patients received a combination of Rituxan and chemotherapy.








